NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

泌尿系統癌症治療藥的全球市場:2020年∼2027年

Global Urological Cancer Drugs Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1008544
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
泌尿系統癌症治療藥的全球市場:2020年∼2027年 Global Urological Cancer Drugs Market - 2020-2027
出版日期: 2021年06月01日內容資訊: 英文 180 Pages
簡介

泌尿系統癌會影響男性和女性泌尿系統的器官和結構,以及男性生殖系統。全球泌尿癌藥物市場的增長受到泌尿癌發病率上升的推動,而報銷政策的擴大是市場增長的主要驅動力之一。

本報告提供全球泌尿系統癌症治療藥市場相關調查分析,提供產業分析,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 全球泌尿系統癌症治療藥市場調查手法與調查範圍

第2章 全球泌尿系統癌症治療藥市場:市場定義與市場概要

第3章 全球泌尿系統癌症治療藥市場:摘要整理

第4章 全球泌尿系統癌症治療藥市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球泌尿系統癌症治療藥市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球泌尿系統癌症治療藥市場:COVID-19分析

  • COVID-19對市場的影響分析
  • 在COVID-19中的價格趨勢
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球泌尿系統癌症治療藥市場:各產品類型

  • 簡介
  • 市場規模分析·與前一年同期比較成長率分析:各產品類型市場區隔
  • 市場魅力指數:各產品類型市場區隔
    • 錠劑
    • 注射

第8章 全球泌尿系統癌症治療藥市場:各適應症

  • 簡介
  • 市場規模分析·與前一年同期比較成長率分析:各適應症
  • 市場魅力指數:各適應症
    • 前列腺癌症
    • 膀胱癌
    • 腎臟癌症

第9章 全球泌尿系統癌症治療藥市場:各終端用戶

  • 簡介
  • 市場規模分析·與前一年同期比較成長率分析:各終端用戶
  • 市場魅力指數:各終端用戶
    • 醫院
    • 手術中心
    • 診斷中心
    • 成像中心
    • 其他

第10章 全球泌尿系統癌症治療藥市場:各地區

  • 簡介
  • 市場規模分析·與前一年同期比較成長率分析:各地區
  • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球泌尿系統癌症治療藥市場:企業簡介

  • Pfizer
  • GlaxoSmithKline Plc.
  • Novartis
  • Roche Healthcare
  • AstraZeneca
  • Abbott Laboratories
  • Sanofi S.A.
  • Bristol-Myers Squibb
  • Celgene corporation
  • Astellas等

第12章 全球泌尿系統癌症治療藥市場:重要考察

第13章 全球泌尿系統癌症治療藥市場:DataM

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global urological cancer drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Urological cancers affect the male and female urinary system's organs and structures and the male reproductive system. These cancers are fairly common. Types of urological cancers are: Bladder cancer affects the cells that line the urinary bladder, a small sac containing urine for excretion. Renal cancer forms in the tiny tubes that clean the blood of the kidneys. Renal pelvic cancer is a rare form of this disease that occurs in the kidney that connects to the bladder. Testicular cancer forms in testis and accounts for only one percent of all cancers in men. Urethral cancer occurs in the urethra, the tube that conducts urine from the bladder to the outside of the body. It is rare and occurs more often in men than in women. Symptoms don't occur until cancer has become more advanced. Blood in the urine (without pain) is a symptom of bladder, kidney and prostate cancer-at later stages, pelvic and back pain can also develop. Patients with prostate cancer may also have other changes in urination and sexual function. Those with testicular or penile cancer may notice a visible lesion on the skin, along with other skin changes or swelling. Any cancer patient can experience weight loss and fatigue. The market is expected to drive in the future due to the high prevalence rate of Urological cancers.

Market Dynamics

The global urological cancer drug market growth is driven by the growing incidence of urological cancers, and growing polices on reimbursement are among the key factors driving market growth.

Increasing incidence of urological cancers, is expected to drive the global urological cancer drug market during the forecast period.

As per the National Cancer Institute( NIH), in 2017, it was estimated 712,614 people were living with bladder cancer in the United States. In 2020, it was estimated that there would be 81,400 new cases of bladder cancer. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States. In 2020, it was estimated that there would be 191,930 new prostate cancer cases, and in 2017, an estimated 558,023 people were living with kidney and renal pelvis cancer in the United States. In 2020, it was estimated that there would be 73,750 new cases of kidney and renal pelvis cancer.

High treatment costs for chemotherapy and radiation therapy are likely to hinder the global leukapheresis market growth.

According to the study by the University of California and San Francisco, there is no standard cost of chemo. However, rough estimations can range from $10,000 to $200,000, and it was also estimated that $19,901 for robot-assisted prostatectomy to treat low-risk disease, to $50,276 for combined radiation therapy for high-risk disease.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the market for Global Urological cancer drugs Market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.

Segment Analysis

Based on the product type, the global urological cancer drugs market is segmented into tablets and injections.

Tablets and Injections segment the global urological drugs market. The tablets segment accounts for the largest share in the urological drugs market. The drugs are classified into Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib), voterint (pazopanib), sutent (sunitinib malate), zytiga (abiraterone acetate), xtandi (enzalutamide), Provenge (sipuleucel-T).

Provenge is the first FDA-approved personalized immunotherapy that is clinically proven to extend life for certain men with advanced prostate cancer. Provenge® (sipuleucel-T) is a prescription drug used to treat certain men with advanced prostate cancer. Provenge is established cellular immunotherapy and is customized to each individual by using his immune cells.

Sutent is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC). In 2018, $1,049 million sales of Sutent occurred.

Xtandi slowed advanced prostate cancer progression. xtandi is FDA-approved to treat three forms of advanced prostate cancer. Men taking xtandi had a 71% lower chance of their cancer progressing than men not taking xtandi.

Zytiga® (abiraterone acetate) is a prescription drug that is used along with prednisone. zytiga® is used to treat men with prostate cancer that has spread to other parts of the body.

Votrient is a cancer drug that interferes with cancer cells' growth and spread in the body, and treats advanced renal cell carcinoma (kidney cancer).

Based on application, the global urological cancer drugs market is segmented into prostate cancer, bladder cancer, kidney cancer.

The prostate cancer segment is expected to drive for the largest share of global urological cancer drugs market. In 2017, the incidence data were available; in the United States, 1,701,315 new cancer cases were reported, and 599,099 people died of cancer. For every 100,000 people, 438 new cancer cases were reported.

In 2017, the incidence data were available; in the United States, 75,047 new Urinary Bladder cancer cases were reported, and 16,657 people died of this cancer. For every 100,000 people, 19 new Urinary Bladder cancer cases were reported.

In 2017, the incidence data were available; in the United States, 65,251 new Kidney and Renal pelvis cancer cases were reported, and 13,959 people died of this cancer. For every 100,000 people, 17 new Kidney and Renal pelvis cancer cases were reported.

Based on End-User, hospitals and surgical centers segment accounted for the largest market share

Due to the growing patient population, the hospitals and surgical centers segment held the largest market share in 2018. Although the rising number of diagnostic laboratories and imaging centers are likely to drive the industry in diagnostic laboratories & imaging centers.

Geographical Analysis

North America served the largest share of the market due to the increasing prevalence of urological cancer diseases. According to the American Cancer Society, the urological cancer prevalence in 2019 estimated was 158,220 urinary system cancers and 174,650 prostate cancers. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, as per the university of south Australia, In 2019, more than 19,500 prostate cancer cases were diagnosed in Australia. Globally, prostate cancer cases reached 1.28 million in 2018. These factors are driving the growth of the market in the forecast period.

Competitive Landscape

The global urological cancer drugs market is quite competitive with some key competitors like Novartis, Pfizer, Roche Healthcare, AstraZeneca, Johnson & Johanson, Astellas, Celgene corporation, Bristol-Myers Squibb, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline Plc. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, According to clinicaltrials.gov;

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Product- As part of Pfizer and Astellas' ongoing commitment to enzalutamide's clinical development, XTANDI is also evaluated in the EMBARK trial in men with high-risk non-metastatic Hormone-sensitive Prostate Cancer.

Key developments:

Why Purchase the Report?

  • Visualize the composition of the global urological cancer drugs market segmentation by product type, by application, by end-user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in urological cancer drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of urological cancer drugs market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global urological cancer drugs market report would provide an access to an approx. market data 61 tables, 52 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Urological Cancer Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Urological Cancer Drugs Market - Market Definition and Overview

3. Global Urological Cancer Drugs Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market snippet by Application
  • 3.3. Market Snippet by End-Users
  • 3.4. Market Snippet by Region

4. Global Urological Cancer Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of urological cancer diseases
      • 4.1.1.2. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of chemotherapy and radiation therapy treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Urological Cancer Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Urological Cancer Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Urological Cancer Drugs Market - By Product Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
  • 7.3. Market Attractiveness Index, By Product Type Segment
    • 7.3.1. Tablet*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Injection

8. Global Urological Cancer Drugs Market - By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.3. Market Attractiveness Index, By Application
    • 8.3.1. Prostate cancer *
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Bladder cancer
    • 8.3.3. Kidney cancer

9. Global Urological Cancer Drugs Market - By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3. Market Attractiveness Index, By End-User
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Surgical centers
    • 9.3.3. Diagnostic centers
    • 9.3.4. Imaging centers
    • 9.3.5. Other

10. Global Urological Cancer Drugs Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Urological Cancer Drugs Market - Company Profiles

  • 11.1. Pfizer*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. GlaxoSmithKline Plc.,
  • 11.3. Novartis.,
  • 11.4. Roche Healthcare.,
  • 11.5. AstraZeneca.,
  • 11.6. Abbott Laboratories.,
  • 11.7. Sanofi S.A.,
  • 11.8. Bristol-Myers Squibb.,
  • 11.9. Celgene corporation.,
  • 11.10. Astellas.

LIST NOT EXHAUSTIVE

12. Global Urological Cancer Drugs Market - Premium Insights

13. Global Urological Cancer Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us